// App-Quantinova.ai

1916 : Robust Efficacy Signals in Elderly AML Patients Treated with Iadademstat in Combination with Azacitidine (ALICE Phase IIa Trial)

Researchers

Presenter

  • Olga Salamero

Principal Investigators

  • Tim C.P Somervaille

  • Antonieta Molero

  • Evelyn Acua

  • Ana Perez

  • Isabel Cano

  • Rebeca Rodrguez-Veiga

  • Sonia Gutierrez

  • Roger Bullock

  • Carlos Buesa

  • Francesc Bosch

  • Pau Montesinos

Medical Centers

  • Department of Hematology, University Hospital Vall d’Hebron, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035, Barcelona, Spain

  • The Christie Hospital, Cancer Research UK Manchester Institute, Manchester, United Kingdom

  • 1. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Departament de Medicina, Universitat Autònoma de Barcelona,, Barcelona, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Department of Microbiology, University Hospital Vall Hebron, Barcelona, Spain

  • Oryzon Genomics, S.A., Cornella De Llobregat, Spain

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Vidaza

  • Hydroxyurea

  • Hydroxycarbamide

  • Iadademstat

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Single Arm

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved